Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 275,767 |
|
|||||
| News | - | ||||||
| Day High | 1.14 | Low High |
|||||
| Day Low | 1.11 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lineage Cell Therapeutics Inc | LCTX | AMEX | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.03 | 2.70% | 1.14 | 18:57:32 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.11 | 1.11 | 1.14 | 1.14 | 1.11 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,096 | 275,767 | US$ 1.13 | US$ 310,472 | - | 0.8414 - 1.61 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:47:56 | 1 | US$ 1.12 | USD |
Lineage Cell Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 213.04M | 188.53M | - | 8.95M | -21.49M | -0.11 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Lineage Cell Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LCTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.22 | 1.23 | 1.10 | 1.13 | 580,767 | -0.08 | -6.56% |
| 1 Month | 1.49 | 1.56 | 1.10 | 1.32 | 932,241 | -0.35 | -23.49% |
| 3 Months | 0.8974 | 1.61 | 0.8816 | 1.25 | 910,344 | 0.2426 | 27.03% |
| 6 Months | 1.12 | 1.61 | 0.8414 | 1.16 | 750,413 | 0.02 | 1.79% |
| 1 Year | 1.34 | 1.61 | 0.8414 | 1.25 | 663,535 | -0.20 | -14.93% |
| 3 Years | 2.50 | 3.00 | 0.8414 | 1.77 | 706,540 | -1.36 | -54.40% |
| 5 Years | 0.9595 | 3.1316 | 0.5339 | 1.63 | 818,787 | 0.1805 | 18.81% |
Lineage Cell Therapeutics Description
| Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures. |
